title: Omalizumab in recurring larynx angioedema: a case report.
abstract: Angioedema with swelling of larynx is a serious allergic reaction and can be life-threatening. It can occur after exposure to various triggers and usually it is very difficult for the patient and the doctor to find the trigger and maintain complete remission. In idiopathic recurring angioedema presenting with frequent attacks, prophylaxis with H1 antihistamines recommended. However, not all patients respond to antihistamines. Omalizumab is an anti-immunoglobulin (Ig)-E-Ig-G antibody approved for the treatment of asthma and also effective treatment in chronic spontaneous urticaria. We report a 47-year-old male patient with severe idiopathic angioedema controlled by corticosteroid and proggressed after discontining of corticosteroid because of its side effects. Omalizumab at a dose of 300 mg every 4 weeks was administrated and omalizumab provided a rapid clinical response after first injection. During the 4 months of omalizumab therapy, he had no further attacks and any other treatment needs. After 3 months of stopping omalizumab therapy, during the 4-week period he had two mild lip swelling in his lips that resolved with antihistamines.
authors.affiliation: Adult Allergy Unit, Göztepe Tainning and Research Hospital, Istanbul Medeniyet University, Istanbul 34469, Turkey.
authors.forename: Ayse Bilge
authors.initials: AB
authors.lastname: Ozturk
authors.affiliation: Department of Dermatology, OkmeydanGı Trainning and Research Hospital, Istanbul 34126, Turkey.
authors.forename: Emek
authors.initials: E
authors.lastname: Kocaturk
keywords: Angioedema; Larynx; Omalizumab